» Articles » PMID: 8657213

Placental Blood As a Source of Hematopoietic Stem Cells for Transplantation into Unrelated Recipients

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1996 Jul 18
PMID 8657213
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Transplantation of bone marrow from unrelated donors is limited by a lack of HLA-matched donors and the risk of graft-versus-host disease (GVHD). Placental blood from sibling donors can reconstitute hematopoiesis. We report preliminary results of transplantation using partially HLA-mismatched placental blood from unrelated donors.

Methods: Twenty-five consecutive patients, primarily children, with a variety of malignant and non-malignant conditions received placental blood from unrelated donors and were evaluated for hematologic and immunologic reconstitution and GVHD. HLA matching was performed before transplantation by serologic typing for class I HLA antigens and low-resolution molecular typing for class II HLA alleles. In donor-recipient pairs who differed by no more than one HLA antigen or allele, high-resolution class II HLA typing was done retrospectively. Fordonor-recipient pairs who were mismatched for two HLA antigens or alleles, high-resolution typing was used prospectively to select the best match for HLA-DRB1.

Results: Twenty-four of the 25 donor-recipient pairs were discordant for one to three HLA antigens. In 23 of the 25 transplant recipients, the infused hematopoletic stem cells engrafted. Acute grade III GVHD occurred in 2 of the 21 patients who could be evaluated, and 2 patients had chronic GVHD. In vitro proliferative responses of T cells and B cells to plant mitogens were detected 60 days after transplantation. With a median follow-up of 12 1/2 months and a minimal follow-up of 100 days, the overall 100-day survival rate among these patients was 64 percent, and the overall event-free survival was 48 percent.

Conclusions: HLA-mismatched placental blood from unrelated donors is an alternative source of stem cells for hematopoietic reconstitution in children.

Citing Articles

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells.

Chmiel J, Stasiak M, Skrzypkowska M, Samson L, Luczkiewicz P, Trzonkowski P Heliyon. 2024; 10(17):e36512.

PMID: 39319132 PMC: 11419861. DOI: 10.1016/j.heliyon.2024.e36512.


Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology.

Mathews D, Abernethy A, Chaikof E, Charo R, Daley G, Enriquez J NAM Perspect. 2024; 2023.

PMID: 38855738 PMC: 11157685. DOI: 10.31478/202311d.


Combating bone marrow failure with polymer materials.

Koch K, Jadon N, Thesmar I, Tew G, Minter L Front Immunol. 2024; 15:1396486.

PMID: 38694497 PMC: 11061490. DOI: 10.3389/fimmu.2024.1396486.


Impact of COVID-19 pandemic on cord blood banking and transplantation.

Rohsig L, Nardi N Cell Tissue Bank. 2024; 25(2):605-611.

PMID: 38168846 DOI: 10.1007/s10561-023-10122-z.


Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration.

Stancioiu F, Bogdan R, Bulumac B, Ivanescu B, Dumitrescu R Maedica (Bucur). 2023; 17(4):885-892.

PMID: 36818273 PMC: 9923064. DOI: 10.26574/maedica.2022.17.4.885.